Sacran polysaccharide improves atopic dermatitis through inhibiting Th2 type immune response

Area of Science:

• Marine biotechnology
• Immunology
• Dermatology

Background:

• Atopic dermatitis (AD) is a chronic inflammatory skin condition.
• Current treatments have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To investigate the therapeutic potential of sacran polysaccharide for atopic dermatitis.
• To elucidate the underlying mechanisms of sacran's anti-dermatitis effects.

Main Methods:

• Established a 2,4-dinitrochlorobenzene (DNCB)-induced AD mouse model.
• Administered varying concentrations of sacran polysaccharide and tacrolimus.
• Assessed dermatitis severity, ear thickness, and behavioral changes.
• Quantified CD4+ and CD8+ T cell populations via flow cytometry.
• Measured Interferon-gamma (Ifng) and Interleukin-4 (Il4) gene expression using real-time quantitative PCR.

Main Results:

• Sacran significantly alleviated AD symptoms, including reduced dermatitis scores, ear thickness, and immunoglobulin E (IgE) levels.
• Sacran demonstrated a potential to mitigate dermatitis by suppressing Th2 cell activation.
• The polysaccharide effectively reduced IgE release, a key marker in allergic inflammation.

Conclusions:

• Polysaccharide sacran exhibits significant anti-dermatitis properties.
• Sacran alleviates dermatitis by inhibiting Th2 cell activation and decreasing IgE release.
• These findings support sacran polysaccharide as a promising candidate for future clinical applications in treating atopic dermatitis.